Evidence map›Paper›PMID 39638936›Full record

ArticleMolecular biology reports2024

Value of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancer.

Doaa Helmy, Ghada Mossallam, Noha Radwan, Amr Kamal, Iman Attia

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Doaa HelmyHelwan University, Cairo, Egypt. doaahelmy@msn.com.
Ghada MossallamClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Noha RadwanClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Amr KamalSurgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Iman AttiaClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to analyse the diagnostic performance of miR200b in epithelial ovarian cancer (EOC) in a group of Egyptian patients and to evaluate the combined use of miR200b with other biomarkers as a reliable diagnostic and prognostic indicator of EOC.

methodsWe tested the expression of cell-free miR200b in 30 EOC patients before undergoing optimum cytoreductive surgery, 19 females with benign ovarian disease and 14 normal healthy females using quantitative real time PCR. All cases were tested for CA125, HE4 and CRP. The results were compared between the three groups. The double combination of miR200b with each biomarker was tested for a possible improvement of the diagnostic power of the test.

resultsMiR200b was significantly overexpressed in EOC patients compared to the other groups, we determined 1.88 folds as the best cutoff for miR200b expression to discriminate between EOC and non-malignant cases with a sensitivity of 63.3% and a specificity of 71%. CA125, HE4 and CRP were evaluated and showed a sensitivity of 96.7%, 45.5%, 81.8% respectively and a specificity of 75.9%, 66.7% and 90% respectively. We evaluated the combined use of miR200b with each biomarker, the best results were seen with the combined use of miR200b and CA125.

conclusionWe concluded that the combined use of miR200b and CA125 could serve as a reliable tool in the initial diagnosis of EOC, and a predictor of event free survival of the disease.

Indexed as

Biomarkers, TumorCA-125 AntigenCarcinoma, Ovarian EpithelialMicroRNAsOvarian NeoplasmsWAP Four-Disulfide Core Domain Protein 2AdultAgedC-Reactive ProteinEgyptFemaleGene Expression Regulation, NeoplasticHumansMembrane ProteinsMiddle AgedPrognosisBiomarkers, TumorCA-125 AntigenC-Reactive ProteinMembrane ProteinsMicroRNAsMIRN200 microRNA, humanMUC16 protein, humanProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanCA125CRPDouble combinationHE4MicroRNAmiR200bmiRNA expressionOvarian cancer

Identifiers

PMID39638936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.